About us

The laboratory of Richard Moriggl (RM) is specialized on kinase and transcription factor research. We question their role in various types of cancers. Work is centered on transgenic mouse analysis and verification of results follows analysis of human patient samples together with clinical oriented research groups. Mouse models display persistent or absent JAK-STAT signaling in combination with additional cancer promoting oncogenes or tumor suppressor gene loss. Moreover, aberrant cytogenetic abnormalities as observed in childhood cancer translocation products are modeled in transgenic mice. We established for the first time a Ewing sarcoma (ES) tumor model through inducible expression of the EWS-FLI1 (EF) translocation product, also an aberrant transcription factor. Translational work is focused on molecular characterization and understanding with therapeutic intervention strategies in myeloproliferative neoplasms (MPN) or Peripheral T cell Leukemia and Lymphoma (PTCL). Recurrent, somatic STAT5 gain-of-function (GOF) mutations or gene dosage of JAK-STAT are of particular interest to us. Improvements in understanding of molecular alterations and their tissue type specific context are essential to enable better targeted therapies.

RM holds a dual endowed professorship with the MedUni and the Vetmeduni Vienna, bridging both universities for translational cancer research. With our research we hope also to bridge the gap between laboratory animal models and human patients. We focus on transgenic cancer mouse models, to investigate core cancer pathways for their roles in driving the establishment or progression of cancer. We will continue to define key molecules of core cancer pathways as oncogenes or tumour suppressors, often specific to particular cell types or diseases. Moreover, oncogenes or tumour suppressors are dependent on the mutational gene driver context, prominent themes in the RM lab. Recent research themes move into Omics and NGS technologies with bioinformatic and systems biology analysis.


About Richard Moriggl

Portrait Richard Moriggl
Portrait Richard Moriggl 1

Richard Moriggl is professor for "Functional Cancer Genomics" in a joint appointment of the University for Veterinary Medicine, Vienna and the Medical University Vienna. He is an internationally reputed expert in JAK/STAT signalling and cancer research. As of June 2016 he has more than 114 PubMed 2 based publications with over 7.300 citations and an h-index of 44 according to his Google Scholar profile 3. He serves continuously as reviewer for internationally reputed journals. In addition to the funding of the LBG and partner institutions towards the LBI-CR, he has been responsible to obtain more than 2.5 M € of external funding towards his research. Richard Moriggl is director and founding member of the LBI-CR since 2006, his group is focused on the JAK-STAT core cancer pathway. The group studies Hematopoietic cancer/Ewing Sarcoma/Metabolism/Malignant Melanoma/Colon Injury and Colorectal Cancer.

He studied biotechnology in Germany and did his PhD in 1997 working on cytokine signaling with Prof. Groner, Friedrich Miescher Institute, Basel, Switzerland and Institute of Experimental Cancer Research, Freiburg, Germany. After a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, USA, in immunology with Prof. Ihle he moved 2000 to the group of Prof. Beug, Institute for Molecular Pathology, in Vienna, studying hematopoiesis and hematopoietic cancer development. Moreover, he made important contributions to the essential interaction of the hepatic glucocorticoid receptor with STAT5 for body growth, sexual differentiation and metabolism. Richard Moriggl was Howard Hughes Medical Institute Postdoctoral Fellow from 1997 to 2000 and he obtained a Marie Curie Fellowship from 2000 to 2002. RM is recipient of several awards including the "Max Buchner-Forschungspreis” (1992), “Otto-Kraupp-Preis” for the Venia Docendi of the Medical Faculty, University of Vienna (2004), “Award of the city of Vienna for research achievements” (2008) and for outstanding scientific achievements in cancer research “Großer zentraleuropäischer Preis, Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung”  (2013).

Curriculum Vitae Richard Moriggl (PDF, 214 KB) 4

Publications - Weblink to VetDoc 5



We are a research team of approximately 10 people, consisting mainly of PhD and Master students with postdocs, all focused on translational cancer research. The group of Richard Moriggl supervises several national and international research projects. Further grant money was attracted through international collaboration.

The RM team in November 2015 at the Castle Seggau Meeting “From Translational Models to Targeted Therapy” in Styria. From left to right: Barbara Maurer (PhD student), Elizabeth Heyes (MSc student), Richard Moriggl (Prof. Dr. DI), Bettina Wingelhofer (PhD student), Alexander Swoboda (postdoc), Doris Kaltenecker (PhD student), Mohammed Elabd (MSc student), Patricia Freund (BMA), Ha Thi Thanh Pham (PhD student), Kristina Müller (Univ. ass. and postdoc), Tahereh Javaheri (PhD student)
Team photo 6